Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.
about
Immunological Landscape and Clinical Management of Rectal CancerPredictive Biomarkers to Chemoradiation in Locally Advanced Rectal CancerNew Perspectives on Predictive Biomarkers of Tumor Response and Their Clinical Application in Preoperative Chemoradiation Therapy for Rectal CancerGenotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancerUDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.The more the messier: centrosome amplification as a novel biomarker for personalized treatment of colorectal cancersCurrent debate in the oncologic management of rectal cancer.Prognostic gene expression profiling in esophageal cancer: a systematic reviewEvaluating microarray-based classifiers: an overviewCyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy.Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy.Integrating chromosomal aberrations and gene expression profiles to dissect rectal tumorigenesisComparability of microarray data between amplified and non amplified RNA in colorectal carcinoma.APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profilingImpact of RNA degradation on gene expression profiling.Functional Genomics and a New Era in Radiation Biology and Oncology.The role of capecitabine in locally advanced rectal cancer treatment: an update.Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients.Expression profiling of rectal tumors defines response to neoadjuvant treatment related genes.Parallel analysis of transcript and translation profiles: identification of metastasis-related signal pathways differentially regulated by drug and genetic modifications.Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patientsImpression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in rectal cancer.Microarray profiling of mononuclear peripheral blood cells identifies novel candidate genes related to chemoradiation response in rectal cancer.Recent advances in the management of carcinoma of the rectumGenes involved in radiation therapy response in head and neck cancersYKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional studyIdentification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancerGenomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study.Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy.The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies.Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patientsGene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.Isolation and solubilization of proteins after TRIzol extraction of RNA and DNA from patient material following prolonged storage.Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas.Aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt/beta-catenin signaling pathway in human rectal carcinomas.An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancerCombined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy.Anti-VEGF therapy: a new approach to colorectal cancer therapy.High-mobility group box 2 (HMGB2) modulates radioresponse and is downregulated by p53 in colorectal cancer cell.
P2860
Q26768531-F8ED6FA0-1283-45CE-B11E-98ED1C7ED283Q26778557-33EF3BE5-AB05-4F70-A7E0-F7B408E6453AQ26786311-39BFC655-0F81-42A0-833D-4BE247A5D6E7Q27007505-6E41871F-0AAB-4A6B-B80B-5B2ED2039128Q27853065-8374BB64-34D0-4325-9316-97B34EEC49E8Q28072910-1DF511E9-7A39-48FD-A20F-87814ADF21F3Q28072948-3E41C8DA-3886-4A50-9894-E981EE3503ACQ28073948-48B7691D-9287-4EAE-A801-5B9D7CA6898BQ28761774-1B2604BD-394A-4F02-B35D-8DB1293A0F30Q30428813-9EE33F41-887D-49BA-933E-589854A69AD1Q31095551-A1668D37-7D64-4A7F-B691-C419C32F01C4Q33380444-1A0092B8-E015-4724-8114-BD6A30642F1FQ33510352-B3728D9C-9371-4147-B9F5-3CF46429E5EAQ33517932-742DDF6E-B744-4030-9259-C10E6B40A1DDQ33652966-32DA918F-FCA6-4A61-B693-51DF07207027Q34218803-D148D28A-0B11-4C46-AA8E-316DE6328CC7Q34276823-35FFEA07-4312-4164-8652-A39EC55E0964Q34437609-CA658355-5AFB-4B75-8EFC-6116B463887AQ34473018-3179F580-8E35-47EE-A8AA-CB11171AC580Q34768155-E2B9F78E-DA9A-4095-A0ED-5257B7057309Q34787505-AC6A1D5E-B239-4844-A7F7-78EABF5414DCQ34932625-ED15AAA3-D7D0-4B84-B23D-1CF2338AE55CQ34989668-3226FD12-ED00-4B08-BAA3-F0CB03B118AEQ35026254-D13F9264-59E3-4EAB-9F92-6B944F40A7FDQ35120745-7A77B6F8-FAC9-46E6-94A9-299E219223D5Q35433475-7DE40140-91FB-490B-B5BC-D6B24FF798F0Q35460703-BC33AA0C-3DB7-4C0F-8C13-E3DBD4085DD9Q35607847-9D3F2C66-0F41-485C-81EE-E3409DB67ADDQ35661951-C7786543-F339-4941-972A-3E38F810488AQ35859128-A0ACDFC3-B2F6-4E88-A78D-DC4C322694F1Q35875892-73983EE9-95EC-4A22-AC76-6FA994BFFCCBQ36211293-EDAFD0D4-3548-4CD8-A07B-AB122F593940Q36481670-B9FA3308-B08D-4339-9501-3E09F32CBCBFQ36487066-A188C554-1C3D-408E-B87C-17E2F1013901Q36487084-661DFE37-8213-406F-A957-6672CAB25C68Q36533581-4A3999A3-0F8D-4E86-8D40-6E2DFD4BF3CDQ36544900-F118844A-66FC-4AD9-8B03-DC76038A7300Q36614764-E28B2C45-D777-4C00-9051-E1C2FDB5059EQ36636633-51A48014-1A89-4DBE-BBAE-979502567A35Q36677697-C723E0EB-E3B6-4976-8990-9F231E368010
P2860
Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Effectiveness of gene expressi ...... reoperative chemoradiotherapy.
@ast
Effectiveness of gene expressi ...... reoperative chemoradiotherapy.
@en
type
label
Effectiveness of gene expressi ...... reoperative chemoradiotherapy.
@ast
Effectiveness of gene expressi ...... reoperative chemoradiotherapy.
@en
prefLabel
Effectiveness of gene expressi ...... reoperative chemoradiotherapy.
@ast
Effectiveness of gene expressi ...... reoperative chemoradiotherapy.
@en
P2093
P2860
P356
P1476
Effectiveness of gene expressi ...... preoperative chemoradiotherapy
@en
P2093
B Michael Ghadimi
Claus Langer
Cristina Montagna
Heinz Becker
Laszlo Füzesi
Marian Grade
Michael J Difilippantonio
Richard Simon
Thomas Ried
Torsten Liersch
P2860
P304
P356
10.1200/JCO.2005.00.406
P407
P50
P577
2005-03-01T00:00:00Z